Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL0020 and Toripalimab in Recurrent Extensive-Stage Small Cell Lung Cancer
NCT07550842Phase 1Not yet recruiting
- Sponsor
- Shanghai Best-Link Bioscience
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL0020 in small cell lung cancer (SCLC), sponsored by Shanghai Best-Link Bioscience. Primary endpoints: Maximum Tolerated Dose at 2 years and Recommended Phase 3 Dose at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
BL0020
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07550842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550842.